LISTING OF THE CLAIMS:

Claim 1 (Currently amended): A method ~~for treating the symptoms of an immediate hypersensitivity reaction caused by an amphiphilic carrier~~ comprising administering ~~to a subject~~ a composition comprising a hypersensitivity reducing effective amount of a complement activation inhibitor, active ingredient(s) and ~~the~~ an amphiphilic carrier to a subject having a condition responsive to the active ingredient(s), wherein said amphiphilic carrier is polyethoxylated oil or a derivatized polyethoxylated oil and is capable of causing an immediate hypersensitivity reaction in the subject, and wherein the active ingredient is taxol, paclitaxel, Doxil, althesin, cyclosporin, diazepham, didemnin E, echinomycin, propandid, steroids, teniposide, doxorubicin, daunorubicin, amphoterin B, hemoglobin, polynucleotide or a multivitamin.

Claim 2 (Currently amended): The method according to claim 1 wherein said composition further comprises a pharmaceutical solvent and ~~additional~~ emulsifiers or detergent.

Claim 3 (Currently amended) The method according to claim 2 wherein the pharmaceutical solvent is ~~selected from the group of~~ a hydrophilic or hydrophobic solvents.

Claim 4 (Previously amended) The method according to claim 1 wherein the polyethoxylated oil is polyethoxylated castor oil.

Claim 5 (Cancel)

Claim 6 (Currently amended) The method according to claim 2 wherein the active ingredient is ~~pharmaceutical composition includes~~ taxol, althesin, cyclosporin, diazepham, didemnin E, echinomycin, propandid, steroids, teniposide[[,]] or multivitamin ~~products~~.

Claim 7 (Withdrawn): A pharmaceutical composition effective for inhibiting, treating, or reducing unwanted side effects caused by a drug composition including a drug and a solvent containing amphiphilic molecules in an individual, said pharmaceutical composition comprising a complement activation inhibitor in a pharmaceutically effective amount.

Claim 8 (Withdrawn): The pharmaceutical composition of claim 7 wherein said solvent contains polythoxylated oil.

Claim 9 (Withdrawn): The pharmaceutical composition of claim 7 wherein said complement activation inhibitor is selected from the group consisting of: sCR1, Factor H, Factor I, C1qInh, soluble forms of DAF, MCP, complestatin, and anti-C5a, compound K-76COOH, diamines, small polyanions, sulfonated aromatic compounds, small synthetic peptide analogues of the C terminal part of C3, CAB-2, indel-proximal peptides, serine esterase inhibitors, chimeric complement inhibitor proteins, and antibodies specific for complement proteins.

Claim 10 (Previously amended): The method of claim 1 wherein the administration includes: administering to said individual the complement activation inhibitor prior to the administration of said active ingredient.

Claim 11 (Withdrawn): An in vitro method for predicting hypersensitivity reactions in an individual resulting from a drug composition containing polyethoxylated oil, said method comprising incubating said drug composition with a sample of said individual's serum in vitro and detecting the presence or absence of complement activation.

Claims 12 and 13 (Previously canceled)

Claim14 (Previously amended): The method according to claim 1 wherein said amphiphilic carrier is selected from the group consisting of liposomes, colloidal dispersions, particulate biomaterials and radiocontrast agents.

Claim 15 (Previously canceled)

Claim 16 (Currently amended): The method according to claim 1wherein said active ingredient ~~drug~~ is doxorubicin, daunorubicin or amphotericin B.

Claim 17 (Currently amended): The method according to claim 1 wherein the ~~pharmaceutical composition includes as an~~ active agent is hemoglobin or polynucleotides.

Claim 18. (Withdrawn) A pharmaceutical composition effective for inhibiting, treating, or reducing unwanted side effects caused by a drug composition including a drug and a carrier containing amphiphilic molecules in an individual, said pharmaceutical composition comprising a complement activation inhibitor in a pharmaceutically effective amount.

Claim 19. (Withdrawn) The pharmaceutical composition of claim 18 wherein said complement activation inhibitor is selected from the group consisting of: sCR1, Factor H, Factor I, C1qInh, soluble forms of DAF, MCP, complestatin, and anti-C5a, compound K-76COOH, diamines, small polyanions, sulfonated aromatic compounds, small synthetic peptide analogues of the C

terminal part of C3, CAB-2, indel-proximal peptides, serine esterase inhibitors, chimeric complement inhibitor proteins, and antibodies specific for complement proteins.

Claim 20. (New) The method according to claim 1 wherein the complement activation inhibitor is selected from the group consisting of: sCR1, Factor H, Factor I, C1qInh, soluble forms of DAF, MCP, complestatin, and anti-C5a, compound K-76COOH, diamines, small polyanions, sulfonated aromatic compounds, small synthetic peptide analogues of the C terminal part of C3, CAB-2, indel-proximal peptides, serine esterase inhibitors, chimeric complement inhibitor proteins, and antibodies specific for complement.

Claim 21. (New) The method according to claim 1 wherein the complement activation inhibitor is sCR1, GS1, Indometacin, PAP, Zymosan, EGTA and anti-lipid antibodies.